Recruiting Breast Cancer Studies in Kansas City
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib plus fulvestrant and CDK4/6 Inhibitors for the treatment of patients with locally advanced o...
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
This study will evaluate the efficacy and safety of the combination of inavolisib plus a cyclin-dependent kinase 4 and 6 inhibitor (CDK4/6i) and letrozole versus placebo plus a CDK4/6i and letrozole i...
Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial
This phase II trial evaluates response-guided low-dose tamoxifen for reducing breast density in women who are at higher than average risk for breast cancer. Increasing breast density is a well establi...
Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC
This study will assess if the presence of immune system cells in and around the tumor impacts tumor shrinkage in patients receiving neoadjuvant chemoimmunotherapy for triple-negative breast cancer....
Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer
This phase IIA trial compares the effect of acolbifene versus low dose tamoxifen in preventing breast cancer in premenopausal women at high risk for developing breast cancer. The usual approach for pa...
Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction
This phase II trial evaluates tamoxifen, with or without omega-3 fatty acids, for reducing risk of breast cancer among postmenopausal and overweight or obese women who are at increased risk of develop...
About Breast Cancer Clinical Trials in Kansas City
Breast cancer is a disease in which cells in the breast grow out of control. It is the most common cancer in women worldwide and can also occur in men. Treatment options include surgery, radiation, chemotherapy, hormone therapy, and targeted therapies.
There are currently 6 breast cancer clinical trials recruiting participants in Kansas City, MISSOURI. These studies are seeking a combined 1,609 participants. Research is being sponsored by Celcuity Inc, Hoffmann-La Roche, National Cancer Institute (NCI) and 1 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Breast Cancer Clinical Trials in Kansas City — FAQ
Are there breast cancer clinical trials in Kansas City?
Yes, there are 6 breast cancer clinical trials currently recruiting in Kansas City, MISSOURI. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Kansas City?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Kansas City research site will contact you about next steps.
Are clinical trials in Kansas City free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Kansas City studies also compensate for your time and travel.
What breast cancer treatments are being tested?
The 6 active trials in Kansas City are testing new therapies including novel drugs, biologics, and treatment approaches for breast cancer.
Data updated March 2, 2026 from ClinicalTrials.gov